After five years of waiting, Pfizer and Lilly are ready to restart late-stage clinical trials for the pain drug tanezumab, the big pharmas announced 23 March. The move forward scores Pfizer a $200m milestone payment and signals a jumpstart for the class of drugs.
Pfizer and Lilly will be able to resume Phase III clinical trials of tanezumab after the FDA gave the greenlight,...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
